Superb news! $REGN all the way_老虎社区_美港股上老虎

2021-08-27

Superb news! $REGN all the way!

3 Growth Stocks Near Record Highs That Are Still Worth Buying<blockquote>3只接近历史新高仍值得买入的成长股</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":819290945,"tweetId":"819290945","gmtCreate":1630071108887,"gmtModify":1704955493502,"author":{"id":3574511579214221,"idStr":"3574511579214221","authorId":3574511579214221,"authorIdStr":"3574511579214221","name":"galvinpangg","avatar":"https://static.tigerbbs.com/f92bc06f60d6b2cd382440f29eea3a45","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Superb news! $REGN all the way!</body></html>","htmlText":"<html><head></head><body>Superb news! $REGN all the way!</body></html>","text":"Superb news! $REGN all the way!","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/819290945","repostId":1108652179,"repostType":4,"repost":{"id":"1108652179","kind":"news","pubTimestamp":1630069658,"share":"https://www.laohu8.com/m/news/1108652179?lang=zh_CN&edition=full","pubTime":"2021-08-27 21:07","market":"us","language":"en","title":"3 Growth Stocks Near Record Highs That Are Still Worth Buying<blockquote>3只接近历史新高仍值得买入的成长股</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108652179","media":"The Motley Fool","summary":"Key Points\n\nOne of these stocks is a pioneer in robotic surgery, a field that's only in its early in","content":"Key Points<blockquote>要点</blockquote> <ul> <li>One of these stocks is a pioneer in robotic surgery, a field that's only in its early innings.</li> <li>Another is a tech giant with strong momentum across multiple areas.</li> <li>The third stock is a big biotech with soaring sales and a promising pipeline.</li> </ul> <blockquote><ul><li>其中一只股票是机器人手术领域的先驱，该领域才刚刚起步。</li><li>另一个是在多个领域势头强劲的科技巨头。</li><li>第三只股票是一家销售额飙升且产品线前景广阔的大型生物技术公司。</li></ul></blockquote> Many investors like to buy high-flying stocks on dips. It's psychologically rewarding in a way. You feel like you're getting a better deal on a stock that has performed really well.<blockquote>许多投资者喜欢逢低买入股价高的股票。在某种程度上，这在心理上是有益的。你觉得你在一只表现非常好的股票上得到了更好的交易。</blockquote> There are two main problems that can arise with this approach, though. First, you might have to wait a long time for those dips and miss out on some big gains. Second, sometimes the dips are the beginning of a much larger downtrend.<blockquote>然而，这种方法可能会出现两个主要问题。首先，您可能需要等待很长时间才能看到这些下跌，并错过一些巨大的收益。其次，有时下跌是更大下跌趋势的开始。</blockquote> Buying stocks that have recently set all-time highs can actually be a better strategy. It only works, however, when the stocks have room to run. The good news is that there are several great picks on the market right now that meet both criteria.&nbsp;Here are three growth stocks near record highs that are still worth buying.<blockquote>购买最近创下历史新高的股票实际上可能是一个更好的策略。然而，只有当股票有上涨空间时，它才会起作用。好消息是，目前市场上有几个符合这两个标准的绝佳选择。以下是三只接近历史高点的成长型股票，仍然值得购买。</blockquote> <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a>'s&nbsp;(NASDAQ:ISRG)&nbsp;shares have soared nearly 30% so far this year. The&nbsp;healthcare stock&nbsp;is only a little under its record level set last week.<blockquote><a href=\"https://laohu8.com/S/ISRG\">直观手术</a>的（纳斯达克：ISRG）股价今年迄今已飙升近30%。该医疗保健股仅略低于上周创下的创纪录水平。</blockquote> It's quite possible that Intuitive Surgical could experience additional momentum in the near future. The company plans toconduct a 3-for-1 stock split&nbsp;in late September, assuming shareholders vote in favor of the move. However, there are much better reasons to consider investing in Intuitive over the long term.<blockquote>直觉外科很可能在不久的将来会经历额外的动力。假设股东投票赞成此举，该公司计划在9月底进行1比3的股票分割。然而，有更好的理由考虑长期投资Intuitive。</blockquote> Robotic surgery is still only in its early innings, even though Intuitive has been selling its da Vinci systems for more than two decades. The company could more than quadruple the number of procedures performed with its robotic surgical systems without adding any regulatory clearances or geographical markets.<blockquote>尽管Intuitive销售达芬奇系统已有二十多年，但机器人手术仍处于早期阶段。该公司可以将其机器人手术系统执行的手术数量增加四倍以上，而无需增加任何监管许可或地理市场。</blockquote> Further technological innovation should enable Intuitive Surgical to expand its opportunities. The company thinks that it could more than triple its current addressable market by introducing new products and winning additional regulatory clearances.<blockquote>进一步的技术创新将使Intuitive Surgical能够扩大其机会。该公司认为，通过推出新产品和赢得额外的监管许可，它可以将目前的目标市场扩大两倍以上。</blockquote> Like Intuitive Surgical,&nbsp;<a href=\"https://laohu8.com/S/MSFT\">Microsoft</a>'s&nbsp;(NASDAQ:MSFT)&nbsp;stock is only around 1% below its all-time high. Shares of the technology giant have soared more than 35% year to date.<blockquote>像直觉外科，<a href=\"https://laohu8.com/S/MSFT\">微软</a>的（纳斯达克：MSFT）股价仅比历史高点低1%左右。今年迄今为止，这家科技巨头的股价已飙升超过35%。</blockquote> There's a good reason why Microsoft is performing so well. Nearly everything that could go right for the company&nbsp;is&nbsp;going right. It reported 21% year-over-year revenue growth in its latest quarter with earnings per share jumping 49%. All three of the company's business units delivered solid growth, with two of them posting revenue increases of at least 25%.<blockquote>微软表现如此出色是有充分理由的。几乎所有对公司有利的事情是往右走。该公司报告最近一个季度的收入同比增长21%，每股收益增长49%。该公司的所有三个业务部门都实现了稳健增长，其中两个业务部门的收入增长了至少25%。</blockquote> Can Microsoft keep this momentum going? I think so. The company's Azure cloud business continues to have strong growth prospects. Enterprise system Dynamics 365 is rapidly picking up market share. The new Windows 11 operating system for PCs launches later this year.<blockquote>微软能保持这种势头吗？我想是的。该公司的Azure云业务继续具有强劲的增长前景。企业系统动态365正在迅速获得市场份额。面向个人电脑的新Windows 11操作系统将于今年晚些时候推出。</blockquote> Currently, around 5% of the world's gross domestic product (GDP) is related to technology. However, Microsoft CEO Satya Nadellasaid in the company's recent quarterly update&nbsp;that he expects the percentage to double on a \"more accelerated pace\" than some have projected. If he's right (and I suspect that he is), Microsoft will likely be a major beneficiary.<blockquote>目前，全球约5%的国内生产总值（GDP）与技术有关。然而，微软首席执行官萨蒂亚·纳德拉(Satya Nadella)在公司最近的季度更新中表示，他预计这一比例将以比一些人预测的“更快的速度”翻一番。如果他是对的（我怀疑他是对的），微软可能会成为主要受益者。</blockquote> <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> (NASDAQ:REGN)&nbsp;ranks as the biggest winner of these three growth stocks in 2021. The biotech's shares are up nearly 40% year to date -- a record level.<blockquote><a href=\"https://laohu8.com/S/REGN\">再生元制药</a>（纳斯达克：REGN）位列这三只成长股2021年的最大赢家。该生物技术公司的股价今年迄今已上涨近40%，创历史新高。</blockquote> In the second quarter, Regeneron's revenue skyrocketed 163% year over year with adjusted earnings per share vaulting 260% higher. COVID-19 antibody cocktail REGEN-COV served as the big catalyst behind those impressive gains.<blockquote>第二季度，再生元的收入同比猛增163%，调整后每股收益飙升260%。新冠肺炎抗体鸡尾酒REGEN-COV是这些令人印象深刻的收益背后的巨大催化剂。</blockquote> It's a near certainty that REGEN-COV will continue to make a lot of money for Regeneron over the next several months with the delta variant wreaking havoc across the world. But how will the company fare when coronavirus concerns fade? My prediction is Regeneron can keep up its winning ways.<blockquote>几乎可以肯定的是，随着德尔塔变异毒株在世界各地造成严重破坏，REGEN-COV将在未来几个月继续为Regeneron赚很多钱。但当冠状病毒担忧消退时，该公司将如何发展？我的预测是再生元能够保持其获胜方式。</blockquote> The big biotech's lineup includes several other products with fast-rising sales, notably including autoimmune-disease drug Dupixent and cancer drug Libtayo. Regeneron also has a pipeline that's loaded with promising antibody therapies targeting a wide range of diseases.<blockquote>这家大型生物技术公司的产品阵容包括其他几种销售额快速增长的产品，特别是自身免疫性疾病药物Dupixent和癌症药物Libtayo。再生元还拥有一条充满针对多种疾病的有前途的抗体疗法的管道。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks Near Record Highs That Are Still Worth Buying<blockquote>3只接近历史新高仍值得买入的成长股</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks Near Record Highs That Are Still Worth Buying<blockquote>3只接近历史新高仍值得买入的成长股</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe Motley Fool2021-08-27 21:07\n\n</h4>\n</header>\n<article>\nKey Points<blockquote>要点</blockquote> <ul> <li>One of these stocks is a pioneer in robotic surgery, a field that's only in its early innings.</li> <li>Another is a tech giant with strong momentum across multiple areas.</li> <li>The third stock is a big biotech with soaring sales and a promising pipeline.</li> </ul> <blockquote><ul><li>其中一只股票是机器人手术领域的先驱，该领域才刚刚起步。</li><li>另一个是在多个领域势头强劲的科技巨头。</li><li>第三只股票是一家销售额飙升且产品线前景广阔的大型生物技术公司。</li></ul></blockquote> Many investors like to buy high-flying stocks on dips. It's psychologically rewarding in a way. You feel like you're getting a better deal on a stock that has performed really well.<blockquote>许多投资者喜欢逢低买入股价高的股票。在某种程度上，这在心理上是有益的。你觉得你在一只表现非常好的股票上得到了更好的交易。</blockquote> There are two main problems that can arise with this approach, though. First, you might have to wait a long time for those dips and miss out on some big gains. Second, sometimes the dips are the beginning of a much larger downtrend.<blockquote>然而，这种方法可能会出现两个主要问题。首先，您可能需要等待很长时间才能看到这些下跌，并错过一些巨大的收益。其次，有时下跌是更大下跌趋势的开始。</blockquote> Buying stocks that have recently set all-time highs can actually be a better strategy. It only works, however, when the stocks have room to run. The good news is that there are several great picks on the market right now that meet both criteria.&nbsp;Here are three growth stocks near record highs that are still worth buying.<blockquote>购买最近创下历史新高的股票实际上可能是一个更好的策略。然而，只有当股票有上涨空间时，它才会起作用。好消息是，目前市场上有几个符合这两个标准的绝佳选择。以下是三只接近历史高点的成长型股票，仍然值得购买。</blockquote> <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a>'s&nbsp;(NASDAQ:ISRG)&nbsp;shares have soared nearly 30% so far this year. The&nbsp;healthcare stock&nbsp;is only a little under its record level set last week.<blockquote><a href=\"https://laohu8.com/S/ISRG\">直观手术</a>的（纳斯达克：ISRG）股价今年迄今已飙升近30%。该医疗保健股仅略低于上周创下的创纪录水平。</blockquote> It's quite possible that Intuitive Surgical could experience additional momentum in the near future. The company plans toconduct a 3-for-1 stock split&nbsp;in late September, assuming shareholders vote in favor of the move. However, there are much better reasons to consider investing in Intuitive over the long term.<blockquote>直觉外科很可能在不久的将来会经历额外的动力。假设股东投票赞成此举，该公司计划在9月底进行1比3的股票分割。然而，有更好的理由考虑长期投资Intuitive。</blockquote> Robotic surgery is still only in its early innings, even though Intuitive has been selling its da Vinci systems for more than two decades. The company could more than quadruple the number of procedures performed with its robotic surgical systems without adding any regulatory clearances or geographical markets.<blockquote>尽管Intuitive销售达芬奇系统已有二十多年，但机器人手术仍处于早期阶段。该公司可以将其机器人手术系统执行的手术数量增加四倍以上，而无需增加任何监管许可或地理市场。</blockquote> Further technological innovation should enable Intuitive Surgical to expand its opportunities. The company thinks that it could more than triple its current addressable market by introducing new products and winning additional regulatory clearances.<blockquote>进一步的技术创新将使Intuitive Surgical能够扩大其机会。该公司认为，通过推出新产品和赢得额外的监管许可，它可以将目前的目标市场扩大两倍以上。</blockquote> Like Intuitive Surgical,&nbsp;<a href=\"https://laohu8.com/S/MSFT\">Microsoft</a>'s&nbsp;(NASDAQ:MSFT)&nbsp;stock is only around 1% below its all-time high. Shares of the technology giant have soared more than 35% year to date.<blockquote>像直觉外科，<a href=\"https://laohu8.com/S/MSFT\">微软</a>的（纳斯达克：MSFT）股价仅比历史高点低1%左右。今年迄今为止，这家科技巨头的股价已飙升超过35%。</blockquote> There's a good reason why Microsoft is performing so well. Nearly everything that could go right for the company&nbsp;is&nbsp;going right. It reported 21% year-over-year revenue growth in its latest quarter with earnings per share jumping 49%. All three of the company's business units delivered solid growth, with two of them posting revenue increases of at least 25%.<blockquote>微软表现如此出色是有充分理由的。几乎所有对公司有利的事情是往右走。该公司报告最近一个季度的收入同比增长21%，每股收益增长49%。该公司的所有三个业务部门都实现了稳健增长，其中两个业务部门的收入增长了至少25%。</blockquote> Can Microsoft keep this momentum going? I think so. The company's Azure cloud business continues to have strong growth prospects. Enterprise system Dynamics 365 is rapidly picking up market share. The new Windows 11 operating system for PCs launches later this year.<blockquote>微软能保持这种势头吗？我想是的。该公司的Azure云业务继续具有强劲的增长前景。企业系统动态365正在迅速获得市场份额。面向个人电脑的新Windows 11操作系统将于今年晚些时候推出。</blockquote> Currently, around 5% of the world's gross domestic product (GDP) is related to technology. However, Microsoft CEO Satya Nadellasaid in the company's recent quarterly update&nbsp;that he expects the percentage to double on a \"more accelerated pace\" than some have projected. If he's right (and I suspect that he is), Microsoft will likely be a major beneficiary.<blockquote>目前，全球约5%的国内生产总值（GDP）与技术有关。然而，微软首席执行官萨蒂亚·纳德拉(Satya Nadella)在公司最近的季度更新中表示，他预计这一比例将以比一些人预测的“更快的速度”翻一番。如果他是对的（我怀疑他是对的），微软可能会成为主要受益者。</blockquote> <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> (NASDAQ:REGN)&nbsp;ranks as the biggest winner of these three growth stocks in 2021. The biotech's shares are up nearly 40% year to date -- a record level.<blockquote><a href=\"https://laohu8.com/S/REGN\">再生元制药</a>（纳斯达克：REGN）位列这三只成长股2021年的最大赢家。该生物技术公司的股价今年迄今已上涨近40%，创历史新高。</blockquote> In the second quarter, Regeneron's revenue skyrocketed 163% year over year with adjusted earnings per share vaulting 260% higher. COVID-19 antibody cocktail REGEN-COV served as the big catalyst behind those impressive gains.<blockquote>第二季度，再生元的收入同比猛增163%，调整后每股收益飙升260%。新冠肺炎抗体鸡尾酒REGEN-COV是这些令人印象深刻的收益背后的巨大催化剂。</blockquote> It's a near certainty that REGEN-COV will continue to make a lot of money for Regeneron over the next several months with the delta variant wreaking havoc across the world. But how will the company fare when coronavirus concerns fade? My prediction is Regeneron can keep up its winning ways.<blockquote>几乎可以肯定的是，随着德尔塔变异毒株在世界各地造成严重破坏，REGEN-COV将在未来几个月继续为Regeneron赚很多钱。但当冠状病毒担忧消退时，该公司将如何发展？我的预测是再生元能够保持其获胜方式。</blockquote> The big biotech's lineup includes several other products with fast-rising sales, notably including autoimmune-disease drug Dupixent and cancer drug Libtayo. Regeneron also has a pipeline that's loaded with promising antibody therapies targeting a wide range of diseases.<blockquote>这家大型生物技术公司的产品阵容包括其他几种销售额快速增长的产品，特别是自身免疫性疾病药物Dupixent和癌症药物Libtayo。再生元还拥有一条充满针对多种疾病的有前途的抗体疗法的管道。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/08/27/3-growth-stocks-near-record-highs-that-are-still-w/\">The Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","MSFT":"微软","ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/08/27/3-growth-stocks-near-record-highs-that-are-still-w/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108652179","content_text":"Key Points\n\nOne of these stocks is a pioneer in robotic surgery, a field that's only in its early innings.\nAnother is a tech giant with strong momentum across multiple areas.\nThe third stock is a big biotech with soaring sales and a promising pipeline.\n\n\nMany investors like to buy high-flying stocks on dips. It's psychologically rewarding in a way. You feel like you're getting a better deal on a stock that has performed really well.\nThere are two main problems that can arise with this approach, though. First, you might have to wait a long time for those dips and miss out on some big gains. Second, sometimes the dips are the beginning of a much larger downtrend.\nBuying stocks that have recently set all-time highs can actually be a better strategy. It only works, however, when the stocks have room to run. The good news is that there are several great picks on the market right now that meet both criteria. Here are three growth stocks near record highs that are still worth buying.\nIntuitive Surgical's (NASDAQ:ISRG) shares have soared nearly 30% so far this year. The healthcare stock is only a little under its record level set last week.\nIt's quite possible that Intuitive Surgical could experience additional momentum in the near future. The company plans toconduct a 3-for-1 stock split in late September, assuming shareholders vote in favor of the move. However, there are much better reasons to consider investing in Intuitive over the long term.\nRobotic surgery is still only in its early innings, even though Intuitive has been selling its da Vinci systems for more than two decades. The company could more than quadruple the number of procedures performed with its robotic surgical systems without adding any regulatory clearances or geographical markets.\nFurther technological innovation should enable Intuitive Surgical to expand its opportunities. The company thinks that it could more than triple its current addressable market by introducing new products and winning additional regulatory clearances.\nLike Intuitive Surgical, Microsoft's (NASDAQ:MSFT) stock is only around 1% below its all-time high. Shares of the technology giant have soared more than 35% year to date.\nThere's a good reason why Microsoft is performing so well. Nearly everything that could go right for the company is going right. It reported 21% year-over-year revenue growth in its latest quarter with earnings per share jumping 49%. All three of the company's business units delivered solid growth, with two of them posting revenue increases of at least 25%.\nCan Microsoft keep this momentum going? I think so. The company's Azure cloud business continues to have strong growth prospects. Enterprise system Dynamics 365 is rapidly picking up market share. The new Windows 11 operating system for PCs launches later this year.\nCurrently, around 5% of the world's gross domestic product (GDP) is related to technology. However, Microsoft CEO Satya Nadellasaid in the company's recent quarterly update that he expects the percentage to double on a \"more accelerated pace\" than some have projected. If he's right (and I suspect that he is), Microsoft will likely be a major beneficiary.\nRegeneron Pharmaceuticals (NASDAQ:REGN) ranks as the biggest winner of these three growth stocks in 2021. The biotech's shares are up nearly 40% year to date -- a record level.\nIn the second quarter, Regeneron's revenue skyrocketed 163% year over year with adjusted earnings per share vaulting 260% higher. COVID-19 antibody cocktail REGEN-COV served as the big catalyst behind those impressive gains.\nIt's a near certainty that REGEN-COV will continue to make a lot of money for Regeneron over the next several months with the delta variant wreaking havoc across the world. But how will the company fare when coronavirus concerns fade? My prediction is Regeneron can keep up its winning ways.\nThe big biotech's lineup includes several other products with fast-rising sales, notably including autoimmune-disease drug Dupixent and cancer drug Libtayo. Regeneron also has a pipeline that's loaded with promising antibody therapies targeting a wide range of diseases.","news_type":1,"symbols_score_info":{"REGN":0.9,"ISRG":0.9,"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":537,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":26,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/819290945"}